204 related articles for article (PubMed ID: 30212388)
1. Evaluation of Urine Choline Levels in Women With and Without Overactive Bladder Syndrome.
Sheyn D; Hijaz AK; Hazlett FE; Dawodu K; El-Nashar S; Mangel JM; Petrikovets A; Mahajan ST
Female Pelvic Med Reconstr Surg; 2020 Oct; 26(10):644-648. PubMed ID: 30212388
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Choline and Acetylcholine Levels in Responders and Nonresponders to Anticholinergic Therapy for Overactive Bladder Syndrome.
Sheyn D; Hijaz AK; Hazlett FE; El-Nashar S; Mangel JM; Li X; Mara E; Mahajan ST
Female Pelvic Med Reconstr Surg; 2020 Dec; 26(12):e91-e96. PubMed ID: 31651539
[TBL] [Abstract][Full Text] [Related]
3. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
Dokmeci F; Cetinkaya SE; Seval MM; Dai O
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
[TBL] [Abstract][Full Text] [Related]
5. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction?
Juliato CRT; Melotti IGR; Junior LCS; Britto LGO; Riccetto CLZ
J Sex Med; 2017 Jul; 14(7):904-909. PubMed ID: 28622875
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Overactive Bladder Symptoms Among Women With Interstitial Cystitis/Bladder Pain Syndrome.
Dubinskaya A; Tholemeier LN; Erickson T; De Hoedt AM; Barbour KE; Kim J; Freedland SJ; Anger JT
Female Pelvic Med Reconstr Surg; 2022 Mar; 28(3):e115-e119. PubMed ID: 35272344
[TBL] [Abstract][Full Text] [Related]
8. Clinical and urodynamic impact of detrusor overactivity in women with overactive bladder.
Jiménez-Cidre MA; López-Fando L; Mora AM;
Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):221-227. PubMed ID: 30862379
[TBL] [Abstract][Full Text] [Related]
9. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
Liu HT; Chen CY; Kuo HC
J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
[TBL] [Abstract][Full Text] [Related]
10. Urinary nerve growth factor in women with overactive bladder syndrome.
Liu HT; Chen CY; Kuo HC
BJU Int; 2011 Mar; 107(5):799-803. PubMed ID: 20804479
[TBL] [Abstract][Full Text] [Related]
11. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Urinary Cytokine Expression and Quality of Life in Patients With Overactive Bladder.
Pillalamarri N; Shalom DF; Pilkinton ML; Winkler HA; Chatterjee PK; Solanki M; Metz CN
Female Pelvic Med Reconstr Surg; 2018; 24(6):449-453. PubMed ID: 28953078
[TBL] [Abstract][Full Text] [Related]
13. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
14. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
15. Severe depression and anxiety in women with overactive bladder.
Melotti IGR; Juliato CRT; Tanaka M; Riccetto CLZ
Neurourol Urodyn; 2018 Jan; 37(1):223-228. PubMed ID: 28407347
[TBL] [Abstract][Full Text] [Related]
16. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
Cardozo L; Staskin D; Currie B; Wiklund I; Globe D; Signori M; Dmochowski R; MacDiarmid S; Nitti VW; Noblett K
Int Urogynecol J; 2014 Dec; 25(12):1655-63. PubMed ID: 24859795
[TBL] [Abstract][Full Text] [Related]
17. Cues to urinary urgency and urge incontinence: how those diagnosed with overactive bladder syndrome differ from undiagnosed persons.
OʼConnell KA; Torstrick A; Victor E
J Wound Ostomy Continence Nurs; 2014; 41(3):259-67. PubMed ID: 24805178
[TBL] [Abstract][Full Text] [Related]
18. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
19. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder.
Pennycuff JF; Schutte SC; Hudson CO; Karp DR; Malykhina AP; Northington GM
Neurourol Urodyn; 2017 Mar; 36(3):740-744. PubMed ID: 27062604
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial.
Chan YT; Zhang HW; Guo YQ; Chan TNH; Kwan YK; Lee CK; Ngan K; Lin ZX
Trials; 2018 Jul; 19(1):376. PubMed ID: 30005707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
